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insert (2). A similar strategy was used in the PROVED, RADI-
ANCE, and DIG studies, which produced mean SDCs in the
range of 0.9 to 1.2 ng/ml. We also agree that the current
therapeutic range for digoxin (0.8 to 2.0 ng/ml) is poorly defined
and is based primarily on toxicity—not efficacy. As Dr. Krohn
states, some patients may have high concentrations (2.0 ng/ml)
without evidence of toxicity, whereas others may have relatively
low concentrations and demonstrate efficacy, a point we are
attempting to make with our study. However, it is clear that, in
general, the higher the concentration, the greater the risk for
toxicity. Our analysis, within the limitations indicated, finds no
evidence for a relationship between serum concentration and
efficacy. Patients who continued digoxin, including those with a
low SDC, did better than those who had it withdrawn. Because
lower SDCs appear to be effective, toxicity can be minimized with
a low dose of digoxin while preserving clinical benefit.
Finally, Dr. Krohn notes the high doses of digoxin used for the
acute management of supraventricular arrhythmias postoperatively,
whereas our analysis focuses on the outpatient management of
patients with chronic heart failure. We would suggest that, for a
number of reasons (age, left ventricular function, renal function,
etc.), these may be two totally different patient populations. Their
handling of digoxin, requirement of higher SDC, and ability to
tolerate a higher SDC may differ as well. Perhaps the most
important point is that the SDC should not serve as the sole
marker for efficacy or toxicity but should be taken into consider-
ation along with the patient’s clinical information. The dose and
SDC should always be individualized for any given patient.
Optimal dosing remains a vital but relatively poorly studied
aspect of cardiovascular therapeutics. We believe our work provides
useful data concerning dosing of digoxin, a medication that
remains among the most commonly prescribed worldwide for heart
failure.
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Long-Term Outcome in Patients
With Apical Hypertrophic Cardiomyopathy
We read with interest the study by Eriksson et al. (1), which
described the long-term outcome in patients with apical hypertro-
phic cardiomyopathy (A-HCM). The characteristic hallmarks of
A-HCM as originally described (2) included the presence of giant
negative T waves and a spade-like configuration at end-diastole on
left ventriculography. Only 47% of their patients had giant
negative T waves at baseline. Other forms of so-called A-HCM
such as that described by Maron et al. (3) relate to cases with apical
distribution of septal hypertrophy with mid-ventricular constric-
tion rather than the typical concentric apical hypertrophy of the
Japanese form. They offer a very different clinical presentation,
electrocardiogram, morphology, and prognosis (4,5).
As described initially in Japan, A-HCM is also found in
non-Japanese patients (4–6) provided one adheres to the original
criteria (2). In a longitudinal study fulfilling the exact “Japanese”
criteria of A-HCM, patients were followed for 5 to 20 years (6).
Sustained ventricular tachycardia in 18% and atrial fibrillation in
another 18% of patients appeared as a very late complication. The
T-wave negativity was reduced in 36% and loss of R-wave voltage
was found in 27% of cases. Thus, patients may lose some of their
electrocardiographic diagnostic characteristics and may develop
life-threatening arrhythmias (6,7). One such patient with normal
coronary arteries who had an automatic internal pacemaker defi-
brillator implanted for recurrent ventricular tachycardia developed
an apical aneurysm with clot and has since died of severe
pulmonary edema. Moreover, knowledge of the possibility of late
aneurysmatic formation in A-HCM in the absence of coronary
artery disease is mandatory to avoid the misdiagnosis of congenital
defects in the form of Cantrell’s syndrome (8,9).
In our study, reduction in T-wave negativity and R-wave
voltage was not associated with myocardial infarction (MI) as
reported by the investigators (1). In what percentage of their
patients were these electrocardiographic changes associated with
MI?
Lacking long-term studies and owing to the rarity of true
A-HCM outside Japan, the prognosis has generally been consid-
ered benign based primarily on Japanese observations. However,
considering recent Japanese experience (7) and our own (6) in
addition to that of Eriksson et al. (1), in whose patients one-third
did develop “unfavorable clinical events and potentially life-
threatening complications, such as myocardial infarction, arrhyth-
mia and stroke,” all suggest that a complacent approach in this
entity is unsafe. Close long-term follow-up is essential to reveal
and manage in time potentially fatal complications, particularly in
the elderly. Additional studies are needed to investigate further the
genetic basis of A-HCM and to define risk-stratification strate-
gies. In our opinion, A-HCM can no longer be viewed as a benign
entity neither inside nor outside Japan.
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REPLY
Although we appreciate the interest of Dr. Abinader concerning
our study on apical hypertrophic cardiomyopathy (A-HCM), (1)
we would like to address the issues he has raised.
First, it is to be recognized that the initial reference to A-HCM
was that of Sakamoto et al. (2) in 1976, not Yamaguchi et al. in
1979 (3), as stated by Dr. Abinader. According to Sakamoto, who
recently reviewed his experience with 126 patients, A-HCM is
quite often associated with giant T-wave negativity on the left
precordial leads (4). However, giant T-wave is not necessary for
the diagnosis, which is based on “thickening of the myocardium of
unknown cause localized and confined to the ventricular apex” as
detected by any one of available imaging techniques (4). This
definition was used in our study. All of our patients had the
thickest myocardium in the apical region of the left ventricle, with
some degree of septal hypertrophy in 16 patients, as demonstrated
by echocardiography or magnetic resonance imaging (MRI). In
that respect, our patients do not resemble the Maron et al. cases
(5), but are identical to those described by Japanese investigators
(2,4).
It is well recognized that A-HCM occurs in non-Japanese
patients (6–8) and represents about 7% of the HCM population in
our center (1). Dr. Abinader refers to his experience of 11 cases
followed for 5 to 20 years, which is similar to ours, dealing with
105 cases followed for 13.6  8.3 years. We are well aware that
patients with A-HCM infarct their apex and may develop mid-
ventricular obstruction and apical aneurysm formation. In our
series, 4 of the 11 patients with myocardial infarction (MI) and
normal coronary arteries developed apical aneurysm; in one patient
a large aneurysm was surgically resected for management of
recurrent ventricular tachycardia. We did not observe a significant
mid-ventricular obstruction in any of these patients. Patients with
apical aneurysms all developed Q-waves, a significant decrease in
R-wave amplitudes and had less T-wave negativity after infarction.
None of the patients who did not have MI or who did not develop
an apical aneurysm had Q-waves. We did not analyze changes in
R-wave amplitudes in our study.
We do not agree with Dr. Abinader’s statement that long-term
studies are lacking due to the rarity of true A-HCM outside Japan.
Our long-term results based on 105 patients followed for up to 32
years indicate that cardiovascular mortality of 0.1% per year in
A-HCM is much lower than in other forms of HCM. Therefore,
the prognosis with regard to mortality is benign. However, the
prognosis is not so benign with regard to cardiovascular morbidity,
as 30% of patients develop serious morbid events such as MI,
arrhythmias, and strokes. We have established risk stratification to
identify the patients most likely to develop these complications.
Finally, we agree with Dr. Abinader that, because of significant
morbidity, A-HCM patients should continue to be followed
closely by cardiologists with special interest in HCM, and that
further genetic studies of this form of HCM are needed.
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Interaction of Herbal Drugs With Digoxin
I enjoyed reading the recent study by Valli and Giardina (1) on
drug interactions of herbal therapies with cardiovascular effects. It
was quite comprehensive. However, I would like to make some
additional comments on the interaction of herbal drugs with
digoxin.
Numerous herbs containing cardiac glycosides have been iden-
tified as containing digoxin-like substances, including milkweed,
lily of the valley, Siberian ginseng, and hawthorne berries (2).
Ginseng may falsely elevate digoxin levels (2). A Chinese herb
called kushen has digoxin-like properties (3). Another
Chinese medicine, which is very popular in Japan (4) and is called
kyushin ( “to save the heart”), has been documented to
crossreact with digoxin assays (5,6). It was determined that one
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